var data={"title":"Thromboangiitis obliterans (Buerger's disease)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Thromboangiitis obliterans (Buerger's disease)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/contributors\" class=\"contributor contributor_credentials\">Jeffrey W Olin, DO</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/contributors\" class=\"contributor contributor_credentials\">John F Eidt, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/contributors\" class=\"contributor contributor_credentials\">Joseph L Mills, Sr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/contributors\" class=\"contributor contributor_credentials\">Kathryn A Collins, MD, PhD, FACS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 18, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thromboangiitis obliterans, also called Buerger's disease, is a nonatherosclerotic, segmental, inflammatory disease that most commonly affects the small to medium-sized arteries and veins of the extremities [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Thromboangiitis obliterans is characterized by highly cellular and inflammatory occlusive thrombus with relative sparing of the blood vessel wall [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"abstract_t\">4</a>]. Patients are young smokers who present with distal extremity ischemia, ischemic digit ulcers or digit gangrene [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/5\" class=\"abstract_t\">5</a>]. The disease is strongly associated with the use of tobacco products and smoking cessation is important to decrease the risk for amputation. The epidemiology, clinical manifestations, diagnosis, and treatment of thromboangiitis obliterans are reviewed here.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thromboangiitis obliterans is more common in countries where tobacco is heavily used, especially among people who make homemade cigarettes from raw tobacco [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/6\" class=\"abstract_t\">6</a>]. As such, thromboangiitis obliterans is most prevalent in the Mediterranean, Middle East and Asia [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/7,8\" class=\"abstract_t\">7,8</a>]. In North America, the prevalence of thromboangiitis obliterans has declined in the past 30 years due to a decline in smoking [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/8,9\" class=\"abstract_t\">8,9</a>]. In other parts of the world, the prevalence of this disease among patients with arterial occlusive disease varies widely, ranging from 0.5 to 5.6 percent in Western Europe to as high as 45 to 63 percent in India. [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/10\" class=\"abstract_t\">10</a>]. </p><p>Men are more commonly affected than women and the typical age of onset is 40 to 45 years. Of patients diagnosed with thromboangiitis obliterans, 70 to 91 percent are male and 11 to 30 percent are female [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/11\" class=\"abstract_t\">11</a>]. However, there are reports of increasing prevalence of disease in women, possibly due to the increasing use of cigarettes among women [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/5,9,11-17\" class=\"abstract_t\">5,9,11-17</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of tobacco is essential for the initiation and progression of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Most patients are heavy cigarette smokers. In one study, patients diagnosed with thromboangiitis obliterans smoked an average of 23 years [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/20\" class=\"abstract_t\">20</a>]. Thromboangiitis obliterans has also been reported in cigar smokers, marijuana users (cannabis arteritis) and those who use smokeless tobacco such as chewing tobacco and snuff [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4,5,21-25\" class=\"abstract_t\">4,5,21-25</a>]. </p><p>Chronic anaerobic periodontal infection may also play a role in the development of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/26,27\" class=\"abstract_t\">26,27</a>]. Nearly two-thirds of patients with thromboangiitis obliterans have severe periodontal disease. In one study, DNA fragments associated with anaerobic bacteria were found within both the arterial lesions and oral cavities of patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/26\" class=\"abstract_t\">26</a>]. However, the prevalence of periodontal disease in smokers without thromboangiitis obliterans is similarly high and thus the association may be confounded. </p><p class=\"headingAnchor\" id=\"H514794264\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thromboangiitis obliterans is a segmental inflammatory, nonatherosclerotic, occlusive vascular disease that affects the small and medium-sized arteries and veins. Pathologically, the condition is distinguished from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus with relative sparing of the vessel wall and, more specifically, sparing of the internal elastic lamina [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/28\" class=\"abstract_t\">28</a>]. Although the disease was recognized and the pathology described over 100 years ago, its pathogenesis is poorly understood [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Three pathologic phases are described (<a href=\"image.htm?imageKey=SURG%2F59478\" class=\"graphic graphic_picture graphicRef59478 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/28,30\" class=\"abstract_t\">28,30</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the acute phase, inflammatory thrombi develop in the arteries and veins, typically of the distal extremities. The thrombus is occlusive and polymorphonuclear leukocytes, micro-abscesses, and multinucleated giant cells may be present, but there is no evidence of fibrinoid necrosis [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/28,31\" class=\"abstract_t\">28,31</a>]. Although the external elastic lamina may show some disruption, the internal elastic lamina is intact. Biopsy of an involved superficial vein that demonstrates acute thrombophlebitis will likely show the characteristic acute phase lesion and is diagnostic of the disease. (See <a href=\"#H461453879\" class=\"local\">'Biopsy'</a> below.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The intermediate (subacute) phase is characterized by progressive organization of the thrombus in the small to medium-sized arteries and veins. (A prominent inflammatory infiltrate is still present within the thrombus but is less in the vessel wall.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the chronic phase, inflammation is no longer present and only organized thrombus and vascular fibrosis remain. The pathological appearance in the chronic phase is indistinguishable from all other types of arterial disease.</p><p/><p>Although smoking tobacco is central to the initiation, continuation and recurrence of disease, the specific role of smoking in the pathogenesis of thromboangiitis is unknown. It is postulated that smoking may cause a delayed type of hypersensitivity or toxic angiitis. Immunohistochemical analyses indicate an inflammatory and immunologic pathogenesis [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/19,32-36\" class=\"abstract_t\">19,32-36</a>]. An increased production of cytokines, and a role of notch signal activation may contribute to the inflammatory response observed in patients with Buerger's disease [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/37,38\" class=\"abstract_t\">37,38</a>]. </p><p>Endothelial dysfunction may also be involved in the pathogenesis of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/39-41\" class=\"abstract_t\">39-41</a>]. High titers of antiendothelial antibodies have been detected in patients with this disorder [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/39\" class=\"abstract_t\">39</a>]. Vascular invasion of not only tunica intima but also the tunica media in affected vessels is clearly demonstrated using endothelial cell-specific antigens &#160; There also appears to be impairment of endothelium-dependent vasodilation in angiographically normal limbs of patients diagnosed with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/42\" class=\"abstract_t\">42</a>]. Abnormalities in endothelin may also play a role. (See <a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">&quot;Coronary artery endothelial dysfunction: Clinical aspects&quot;</a>.)</p><p>Prothrombotic factors may also play a role in the pathogenesis of thromboangiitis obliterans. The presence of anticardiolipin antibodies is associated with an increased risk and severity of disease [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/43,44\" class=\"abstract_t\">43,44</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thromboangiitis obliterans typically presents in young smokers less than 40 to 45 years of age. Vascular involvement in thromboangiitis obliterans usually begins with the distal arteries and veins, followed by more proximal arterial occlusive disease. Two or more extremities are usually involved [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4,16\" class=\"abstract_t\">4,16</a>]. A seasonal variation has also been reported with patients more likely to present in the winter [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Superficial thrombophlebitis can occur as a very early disease manifestation even before symptoms and signs, such as extremity pain or digit ischemia, become clinically evident. The presence of superficial phlebitis distinguishes this disorder from other occlusive vascular diseases, though phlebitis may also be observed in Behcet syndrome (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>). </p><p>The migratory phlebitis consists of tender nodules that follow a venous distribution, and frequently parallel arterial disease activity [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/12,45\" class=\"abstract_t\">12,45</a>]. When superficial nodules are present, they should be biopsied to establish a histologic diagnosis. (See <a href=\"#H461453879\" class=\"local\">'Biopsy'</a> below.)</p><p>Digit (toe, finger) ischemia is the most common presentation of thromboangiitis obliterans. One report of 112 patients found that 66 percent had ischemic ulcerations at the time of presentation [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/12\" class=\"abstract_t\">12</a>]. Patients usually note pain and subsequently discoloration of the digits, which can progress to ischemic ulcerations in the upper or lower extremity with accompanying ischemic pain or gangrene of the fingers or toes (<a href=\"image.htm?imageKey=SURG%2F80866\" class=\"graphic graphic_picture graphicRef80866 \">picture 2</a>). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower extremity ulcers occurred in 46 percent, upper extremity ulcers in 28 percent and ulcers in both upper and lower extremities in 26 percent in one series [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/46\" class=\"abstract_t\">46</a>].&nbsp;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another group reported that two limbs were affected in 16 percent of patients, three limbs in 41 percent and all four limbs in 43 percent [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/11\" class=\"abstract_t\">11</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combined upper and lower extremity disease occurred in 20 percent of patients [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/17\" class=\"abstract_t\">17</a>] </p><p/><p>Raynaud's phenomenon occurs in approximately 40 percent of patients and may be asymmetric. However, the frequency of Raynaud's may depend upon the population studied [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-raynaud-phenomenon\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the Raynaud phenomenon&quot;</a>.)</p><p>As the disease progresses, it may involve more proximal arteries. Large artery involvement is unusual and rarely occurs in the absence of small vessel occlusive disease [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/16\" class=\"abstract_t\">16</a>]. If vessels proximal to the wrist or ankle become involved, the patient may complain of claudication of the feet, calves, thighs, or pain in the hands or arms with activity [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"abstract_t\">4</a>]. Symptoms of claudication due to thromboangiitis obliterans may be indistinguishable from those due to other vascular occlusive diseases. Foot claudication is often mistaken for an orthopedic problem. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-lower-extremity-peripheral-artery-disease\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of lower extremity peripheral artery disease&quot;</a>.) </p><p>In a minority of patients, joint complaints may be the first indication of clinical disease. In one study, arthralgias and arthritis were reported in 12.5 percent of patients, typically in the preocclusive phase [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/45\" class=\"abstract_t\">45</a>]. The most commonly affected joints were the wrists and knees. The duration of joint symptoms prior to the digit ischemia can be months to years. The joint manifestations of thromboangiitis obliterans do not lead to erosive arthritis and are frequently episodic, generally resolving within two weeks.</p><p>Although thromboangiitis obliterans most commonly affects the small and medium arteries of the extremities, the pathologic findings have been reported in cerebral, coronary, internal thoracic, renal and mesenteric arteries [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/48-50\" class=\"abstract_t\">48-50</a>]. Symptoms from intestinal or multi-organ involvement are rare but have been reported [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Involvement of large vessels, such as the aorta and iliac arteries, is rare [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/16\" class=\"abstract_t\">16</a>]. Occlusive disease of these vessels is more likely to be due to atherosclerotic peripheral artery disease.</p><p class=\"headingAnchor\" id=\"H514794398\"><span class=\"h1\">CLINICAL AND LABORATORY EVALUATION</span></p><p class=\"headingAnchor\" id=\"H87000089\"><span class=\"h2\">Vascular evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients should have a thorough history and detailed vascular examination. The extremities should be inspected for superficial venous nodules and cords, and the hands and feet examined for evidence of ischemia. Neurologic examination may document peripheral nerve involvement with sensory abnormalities in up to 70 percent of patients [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"abstract_t\">4</a>]. The physical examination alone cannot distinguish arterial occlusive disease due to thromboangiitis obliterans from other etiologies (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>). Given that smoking is a common risk factor, it is not surprising that atherosclerotic peripheral artery disease and thromboangiitis obliterans are often superimposed.</p><p>For patients with lower extremity signs and symptoms, an ankle brachial-index (ABI) should be performed. A normal ABI does not exclude thromboangiitis obliterans, because disease may be limited to the distal vasculature. Thus, digit pressures should be obtained. For patients with upper extremity involvement, a wrist-brachial index should be performed. As with the ankle-brachial index, a normal value may not exclude disease. One novel study used duplex ultrasonography to demonstrate corkscrew collaterals, which can be seen in patients with thromboangiitis obliterans, as well as other small vessel occlusive diseases [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=noninvasive-diagnosis-of-arterial-disease#H58544655\" class=\"medical medical_review\">&quot;Noninvasive diagnosis of arterial disease&quot;, section on 'Ankle-brachial index'</a> and <a href=\"topic.htm?path=noninvasive-diagnosis-of-arterial-disease#H58549402\" class=\"medical medical_review\">&quot;Noninvasive diagnosis of arterial disease&quot;, section on 'Wrist-brachial index'</a>.)</p><p>An Allen test should also be performed (<a href=\"image.htm?imageKey=CARD%2F79685\" class=\"graphic graphic_picture graphicRef79685 \">picture 3</a>). A positive Allen test at the wrist in a young smoker with lower extremity digit ischemia is suggestive of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/2\" class=\"abstract_t\">2</a>]. Methods for performing the Allen test and the hand and foot, and adjunctive use of duplex ultrasound are discussed in detail elsewhere. (See <a href=\"topic.htm?path=arterial-blood-gases#H5\" class=\"medical medical_review\">&quot;Arterial blood gases&quot;, section on 'Ensure collateral circulation'</a>.)</p><p>Patients suspected of having arterial occlusive disease due to thromboangiitis obliterans but who have abnormal ABIs should be referred to the vascular laboratory for additional studies (eg, segmental pressures, pulse volume recordings) to identify patients with proximal vascular disease who may benefit from intervention (stent, bypass). </p><p>The distal circulation can be evaluated using digital plethysmography which may demonstrate one or more flattened digit waveforms supporting the diagnosis. However, digital plethysmography cannot distinguish disease due to thromboangiitis obliterans from other causes of small vessel occlusive disease that affect the digital arteries (eg, scleroderma). (See <a href=\"topic.htm?path=noninvasive-diagnosis-of-arterial-disease#H86998053\" class=\"medical medical_review\">&quot;Noninvasive diagnosis of arterial disease&quot;, section on 'Digit waveforms'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no specific laboratory tests to diagnose thromboangiitis obliterans. The purpose of laboratory studies is to exclude other entities that cause occlusive vascular disease such as diabetes, the vasculitides (eg, lupus, mixed connective tissue disease, scleroderma, CREST syndrome) and thrombophilias (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>). The laboratory evaluation of vasculitis and thrombophilia is discussed elsewhere. (See <a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults#H24\" class=\"medical medical_review\">&quot;Overview of and approach to the vasculitides in adults&quot;, section on 'Laboratory tests'</a> and <a href=\"topic.htm?path=evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors#H25\" class=\"medical medical_review\">&quot;Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors&quot;, section on 'Hypercoagulable tests'</a>.)</p><p>Patients should undergo a complete blood count with differential, a chemistry panel including fasting blood sugar, liver enzymes, renal function, urinalysis and a serologic profile which includes the following [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/2,4\" class=\"abstract_t\">2,4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute phase reactants &ndash; Westergren sedimentation rate (ESR), C-reactive protein (CRP) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunologic panel &ndash; antinuclear antibody (ANA), rheumatoid factor (RF), complement measurements, anticentromere antibody and SCL70 (markers for scleroderma and limited scleroderma [formally called CREST (calcinosis, Raynaud's, esophageal dysmotility, sclerodactyly, telangiectasias)] syndrome. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete hypercoagulability screen &ndash; coagulation tests, antiphospholipid antibodies, anticardiolipin antibodies, protein C, protein S, antithrombin III, factor V Leiden and prothrombin gene mutation </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxicology panel &ndash; cocaine, amphetamines, cannabis</p><p/><p>These tests are normal or negative in patients with thromboangiitis obliterans. However, anticardiolipin antibodies may be present in some patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/43,54\" class=\"abstract_t\">43,54</a>]. In addition, cannabis arteritis is clinically and pathologically indistinguishable from TAO in the absence of cannabis. </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical examination along with testing to exclude other conditions usually suffices to establish the diagnosis [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/11,55-57\" class=\"abstract_t\">11,55-57</a>]. However, for patients with arterial disease established on noninvasive vascular studies who have clinical symptoms and signs consistent with but not definitive for thromboangiitis obliterans, a catheter-based arteriogram may be obtained to look for typical findings and identify the nature and extent of disease [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/58\" class=\"abstract_t\">58</a>]. </p><p>Although gadolinium-enhanced magnetic resonance angiography (MRA) or multidetector computed tomographic angiography (CTA) can be used to image the vasculature, these modalities may still not provide sufficient spatial resolution to provide adequate anatomic detail of the vasculature of the hands and feet. </p><p>When a catheter-based arteriogram is obtained, we prefer to obtain an arteriogram of the upper and lower extremities including the aorta (thoracic and abdominal), even in patients who present with clinical involvement of only one extremity, because of the high prevalence of disease in multiple limbs. Angiographic abnormalities consistent with thromboangiitis obliterans can be seen in limbs that are not yet clinically involved. Arteriographic features suggestive of thromboangiitis obliterans include (<a href=\"image.htm?imageKey=CARD%2F64278\" class=\"graphic graphic_diagnosticimage graphicRef64278 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/2,57-59\" class=\"abstract_t\">2,57-59</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No evidence of atherosclerosis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No source for thromboembolism (eg, aneurysmal disease)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Involvement of small and medium-sized vessels such as the plantar, tibial, peroneal, palmar, radial, and ulnar arteries</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Segmental occlusion with diseased segments interspersed between normal appearing segments </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Collateralization around areas of occlusion (ie, corkscrew collaterals).</p><p/><p>Although the angiographic findings given above, including the presence of corkscrew collaterals, are suggestive, they are not pathognomonic for thromboangiitis obliterans since they may be found in patients with other causes of small vessel occlusive disease. </p><p>The arteriographic findings in patients with cocaine, amphetamine or cannabis ingestion, including the presence of corkscrew collaterals, may also mimic those of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/23-25,60,61\" class=\"abstract_t\">23-25,60,61</a>]. Therefore, in patients who present with manifestations of thromboangiitis obliterans, it is advisable to obtain a toxicology screen for cocaine, amphetamine and cannabis. (See <a href=\"#H8\" class=\"local\">'Laboratory tests'</a> above.)</p><p>A cardiac source of thromboembolism should also be ruled out. The diagnosis of cardiac embolic sources is discussed in detail separately. (See <a href=\"topic.htm?path=echocardiography-in-detection-of-cardiac-and-aortic-sources-of-systemic-embolism\" class=\"medical medical_review\">&quot;Echocardiography in detection of cardiac and aortic sources of systemic embolism&quot;</a>.) </p><p>If surgical revascularization is planned, and if preoperative testing suggests the presence of concomitant ischemic heart disease that requires subsequent cardiac catheterization, then consideration should be given to performing arteriography of the internal thoracic arteries. As noted above, involvement of these arteries may occasionally occur in thromboangiitis obliterans, and planning for coronary bypass surgery is facilitated if their patency is assessed prior to heart surgery. (See <a href=\"#H17\" class=\"local\">'Revascularization'</a> below.)</p><p class=\"headingAnchor\" id=\"H86999828\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thromboangiitis obliterans is a predominantly clinical diagnosis that should be suspected in young patients who smoke and who present with ischemia of the hands <span class=\"nowrap\">and/or</span> feet. However, the diagnosis of thromboangiitis obliterans may be a diagnosis of exclusion after ruling out other more common entities which may produce similar clinical symptoms. Biopsy provides a definitive diagnosis, but subcutaneous nodules are not always present. A clinical diagnosis can be established based upon a scoring system using clinical, angiographic, histopathological, and exclusionary criteria [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/5,62\" class=\"abstract_t\">5,62</a>].</p><p>Thromboangiitis obliterans is differentiated from other entities that cause vascular occlusive disease (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>), the most common of which are discussed below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atherosclerotic peripheral artery disease &ndash; The distal nature of thromboangiitis obliterans and involvement of the lower and upper extremities helps to distinguish the disorder from atherosclerosis. Other risk factors for peripheral artery disease, such as hypertension and hypercholesterolemia, may be absent. In the absence of a histological diagnosis of the acute phase lesion, a diagnosis of diabetes mellitus excludes thromboangiitis obliterans.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thromboembolic disease &ndash; Patients with thromboangiitis obliterans will not have a proximal source for embolism (cardiac, aneurysmal disease) or laboratory evidence of a thrombophilia, though anticardiolipin antibodies may be present.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vasculitis &ndash; Although distal vessel involvement causes distal ischemia in other vasculitides, serologic markers are negative in thromboangiitis obliterans.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Repetitive trauma &ndash; These patients have an occupational history (eg, jackhammer operator) to suggest the mechanism of small vessel disease.</p><p/><p class=\"headingAnchor\" id=\"H86999781\"><span class=\"h2\">Clinical criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A clinical diagnosis can be established with the following commonly used criteria [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/55,56,63\" class=\"abstract_t\">55,56,63</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age less than 45 years</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Current or recent history of tobacco use</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Distal extremity ischemia (objectively noted on vascular testing) (See <a href=\"#H87000089\" class=\"local\">'Vascular evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical arteriographic findings of thromboangiitis obliterans (See <a href=\"#H9\" class=\"local\">'Imaging studies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>) </p><p/><p class=\"headingAnchor\" id=\"H461453879\"><span class=\"h2\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biopsy is rarely needed but is the only means to establish a definitive diagnosis. Patients with subcutaneous nodules or superficial thrombophlebitis should undergo biopsy. Biopsy is suggested if the patient presents with unusual characteristics such as large artery involvement, age &gt;45 years or the presence of elevated anticardiolipin antibodies. Patients with antiphospholipid syndrome exhibit thrombus without inflammation ruling out a diagnosis of thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/43\" class=\"abstract_t\">43</a>].</p><p>If there are no nodules and the patient fulfills the above criteria, a biopsy of an artery or examination of the vein or arteries in an amputated digit or limb may provide a diagnosis; however, this is rarely done. </p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">MEDICAL MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Smoking cessation is the only definitive therapy for patients diagnosed with thromboangiitis obliterans. Although a number of other therapies have been investigated, these should be considered palliative.</p><p>Digit ulcerations are managed as with other ischemic wounds, debridement and moist dressing. Negative pressure wound therapy is becoming popular for the management of open wounds and has been used in the management of open wounds associated with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/64\" class=\"abstract_t\">64</a>]. General considerations for the clinical assessment and management of open wounds are discussed in elsewhere. (See <a href=\"topic.htm?path=clinical-assessment-of-wounds\" class=\"medical medical_review\">&quot;Clinical assessment of wounds&quot;</a> and <a href=\"topic.htm?path=negative-pressure-wound-therapy\" class=\"medical medical_review\">&quot;Negative pressure wound therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Smoking cessation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend that patients discontinue cigarette smoking or the use of tobacco in any form because it is the only effective strategy for managing thromboangiitis obliterans. Complete abstinence from tobacco products is the only way to halt the progression of thromboangiitis obliterans and to avoid future amputations [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"abstract_t\">4</a>]. The disease may be activated by smoking as little as one or two cigarettes a day. Transdermal nicotine patches and nicotine chewing gum should be avoided because they may also keep the disease active, but <a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">bupropion</a> or <a href=\"topic.htm?path=varenicline-drug-information\" class=\"drug drug_general\">varenicline</a> can be used as smoking cessation aids. The correlation between smoking and disease activity is so strong that measurement of urinary nicotine and cotinine (a byproduct of nicotine) should be performed if the disease is active despite patient claims of tobacco cessation [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/65\" class=\"abstract_t\">65</a>]. (See <a href=\"topic.htm?path=overview-of-smoking-cessation-management-in-adults\" class=\"medical medical_review\">&quot;Overview of smoking cessation management in adults&quot;</a>.)</p><p>Patients can be reassured that if they are able to discontinue tobacco use, the disease will remit and the need for amputation is low provided critical limb ischemia (gangrene and tissue loss) has not already occurred. However, the patient may continue to experience intermittent claudication or Raynaud's phenomenon. (See <a href=\"#H87000741\" class=\"local\">'Outcomes'</a> below.)</p><p>Unfortunately, only approximately one-half of patients are able to maintain smoking cessation long term [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/12,66\" class=\"abstract_t\">12,66</a>]. In one series of 110 patients, only 41 (37 percent) were able to discontinue smoking [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/66\" class=\"abstract_t\">66</a>]. Inpatient nicotine dependence treatment is an alternative for recidivist smokers [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/67\" class=\"abstract_t\">67</a>]. </p><p class=\"headingAnchor\" id=\"H268457206\"><span class=\"h2\">Iloprost</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">Iloprost</a> is a prostaglandin analog used to manage pain associated with thromboangiitis obliterans. Intravenous iloprost is more effective than the oral formulation [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/68-71\" class=\"abstract_t\">68-71</a>]. The major benefit of iloprost may be in helping patients with critical limb ischemia get through the period of initial smoking cessation. Two randomized trials have evaluated its effectiveness. </p><p>In one trial, 152 patients were randomly assigned to a six-hour daily intravenous infusion of the drug versus low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/69\" class=\"abstract_t\">69</a>]. Total relief of pain at rest and complete healing of all trophic changes were the primary outcome measures. At 28 days and at six months there was a significant improvement in the iloprost-treated group compared with the aspirin group, with 6 percent of patients in the <a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">iloprost</a> group requiring amputation compared with 18 percent of those receiving aspirin. </p><p>In another trial, 200 patients were randomly assigned to lumbar sympathectomy or intravenous <a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">iloprost</a> [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/70\" class=\"abstract_t\">70</a>]. Rates of ulcer healing were significantly higher in the iloprost group compared with the lumbar sympathectomy group (62 versus 41 percent). Analgesic requirements were less and pain scores lower with iloprost treatment. A prospective study in 158 patients also noted benefits with respect to ulcer healing in patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/71\" class=\"abstract_t\">71</a>]. </p><p>A systematic review that included five trials (602 participants) found moderate-quality evidence that <a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">iloprost</a> was more effective compared with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> for improving rest pain and healing ischemic ulcers intravenously [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/72\" class=\"abstract_t\">72</a>]. Oral iloprost was not more effective than placebo. </p><p class=\"headingAnchor\" id=\"H268457398\"><span class=\"h2\">Calcium channel blockers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Calcium channel blockers are frequently used to manage vasospasm associated with the Raynaud phenomenon. When significant vasospasm is present in patients with thromboangiitis obliterans, calcium channel blocking agents such as <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">nifedipine</a>, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a> or <a href=\"topic.htm?path=amlodipine-drug-information\" class=\"drug drug_general\">amlodipine</a> may similarly be used [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"abstract_t\">4</a>] (See <a href=\"topic.htm?path=initial-treatment-of-the-raynaud-phenomenon#H188847417\" class=\"medical medical_review\">&quot;Initial treatment of the Raynaud phenomenon&quot;, section on 'Calcium channel blockers'</a>.) </p><p class=\"headingAnchor\" id=\"H268457455\"><span class=\"h2\">Intermittent pneumatic compression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Application of intermittent pneumatic compression (IPC) to the foot and calf augments popliteal artery flow through a sharp decrease in peripheral arterial resistance manifested by increases in peak systolic and end diastolic flow velocities on Doppler ultrasound [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Intermittent pneumatic compression enhances calf inflow in patients with intermittent claudication or critical limb ischemia. In one study, complete healing of ischemic ulcers was demonstrated in patients with small vessel occlusive diseases such as scleroderma, CREST and thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/74\" class=\"abstract_t\">74</a>]. We utilize this therapy in patients with painful ulcerations when there is no viable revascularization option. It is useful in decreasing pain even before complete ulcer healing occurs. While there are limited studies, specifically in thromboangiitis obliterans, studies have demonstrated efficacy in small vessel occlusive disease of many etiologies. (See <a href=\"#H17\" class=\"local\">'Revascularization'</a> below.)</p><p class=\"headingAnchor\" id=\"H268457277\"><span class=\"h2\">Experimental therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of additional therapies have been studied or are under active clinical investigation [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/46\" class=\"abstract_t\">46</a>]. Some of these are highlighted below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Therapeutic angiogenesis has been evaluated for treatment of peripheral artery disease and this therapy may improve the ischemic manifestations of thromboangiitis obliterans. Short-term results of therapeutic angiogenesis using growth factors or autologous bone marrow have been promising, but longer term studies are needed.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In one trial of six patients with nonhealing wounds (&gt;1 month), intramuscular vascular endothelial growth factor (VEGF) 165 was injected into seven affected limbs [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/75\" class=\"abstract_t\">75</a>]. Ulcers completely healed in three of five limbs. In the other two patients, nocturnal rest pain was relieved, although both continued to have claudication. In all seven limbs, perfusion was improved on magnetic resonance imaging and newly visible collateral vessels were seen on contrast angiography.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A second phase one trial tested the safety of intramuscular gene transfer by using naked plasmid DNA encoding the gene for VEGF in seven patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/76\" class=\"abstract_t\">76</a>]. Ischemic pain in the affected limb was relieved or improved markedly in six of seven patients, and ischemic ulcers healed or improved in four of six patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cell-based therapy with autologous bone marrow mononuclear cell implantation has also been used with some degree of success [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/77\" class=\"abstract_t\">77</a>]. A meta-analysis indicates that intramuscular autologous bone marrow cell therapy is a feasible, relatively safe and potentially effective therapeutic strategy for patients with severe peripheral artery disease who are not candidates for traditional revascularization [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/78\" class=\"abstract_t\">78</a>]. The therapeutic angiogenesis by cell transplantation (TACT) trial, which included patients with thromboangiitis obliterans, randomly assigned patients to autologous bone marrow mononuclear cell injection versus placebo [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/79\" class=\"abstract_t\">79</a>]. Significant improvements were seen in leg pain scale, ulcer size and pain-free walking distance that were maintained at two years after therapy. Other available small nonrandomized studies have shown similar short-term improvements [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/80-83\" class=\"abstract_t\">80-83</a>]. A confounding factor for many of these studies is the fact that, in addition to receiving therapy, many of the patients stopped smoking. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunoabsorption therapy was tested in a pilot study of 10 patients. The treatment was tolerated without side effects. Pain intensity decreased rapidly from a mean of 7.<span class=\"nowrap\">7/10</span>.0 before treatment to 2.<span class=\"nowrap\">0/10</span>.0 at the second day of five consecutive days of therapy [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/84\" class=\"abstract_t\">84</a>]. One month after immunoabsorption, all patients were without pain, an effect that persisted over the follow-up period of six months. Healing of ischemic ulcerations was observed in all patients during follow-up. Six of the ten patients were studies were active smokers and smoking habits were reported not to change throughout the course of the study. Although the results are encouraging, the sample size of this observational study was quite small; a randomized trial would be needed to prove efficacy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another method of stimulating angiogenesis using a Kirschner wire placed in the medullary canal of the tibia was used in six patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/85\" class=\"abstract_t\">85</a>]. At a mean follow-up of 19 months, significant improvements were seen in symptoms with reduced rest pain, increased pain-free walking distance and ulcer healing. Most studies have not reported significant adverse events to angiogenic therapy; however, in one study, four of eight patients suffered significant clinical events underscoring the need for long-term monitoring [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/86\" class=\"abstract_t\">86</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=bosentan-drug-information\" class=\"drug drug_general\">Bosentan</a>, which is an endothelin receptor antagonist, was used to treat 12 patients with thromboangiitis obliterans and ischemic ulceration or rest pain [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/87\" class=\"abstract_t\">87</a>]. An increase in distal flow was observed in 10 out of the 12 patients on magnetic resonance and digital subtraction arteriography and clinical improvement was observed in 12 of the 13 extremities; however, 2 extremities subsequently required amputation. In a separate series of 26 patients, a complete therapeutic response was achieved in 80 percent of patients, whereas a partial response was observed in 12 percent [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/88\" class=\"abstract_t\">88</a>]. No significant differences were found for bosentan efficacy when comparing patients who gave up smoking with those who were unable to completely abstain from smoking during follow-up.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cilostazol-drug-information\" class=\"drug drug_general\">Cilostazol</a> is a phosphodiesterase inhibitor that suppresses platelet aggregation and is a direct arterial vasodilator [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/89\" class=\"abstract_t\">89</a>]. It is often used in the treatment of peripheral artery disease. In one small study, flow improvements measured in response to reactive hyperemia were significantly increased after two weeks of cilostazol therapy [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/90\" class=\"abstract_t\">90</a>]. Case reports treating patients with digital ischemia with cilostazol have reported improvements in digit pain and ulceration [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/91\" class=\"abstract_t\">91</a>]. </p><p/><p class=\"headingAnchor\" id=\"H234644233\"><span class=\"h1\">INTERVENTION</span></p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Revascularization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical revascularization is usually not indicated due to the distal nature of occlusive disease and because most patients do well with smoking cessation. It has been our experience that surgery is rarely needed if the patient is able to stop smoking. (See <a href=\"topic.htm?path=treatment-of-chronic-limb-threatening-ischemia\" class=\"medical medical_review\">&quot;Treatment of chronic limb-threatening ischemia&quot;</a>.)</p><p>Bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Surgical bypass with autologous vein [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/92-94\" class=\"abstract_t\">92-94</a>] or even omental graft may allow limb salvage [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/95,96\" class=\"abstract_t\">95,96</a>].Although the long-term vein graft patency is less than that seen with peripheral artery disease, limb salvage rates are reasonable and generally greater than 90 percent [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/7,97\" class=\"abstract_t\">7,97</a>]. A possible explanation is that patent grafts, even over a short period of time, are sufficient to allow healing of ulcers in patients with thromboangiitis obliterans. Ulcers are not likely to develop or recur provided the patient is compliant with smoking cessation.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective review of 71 bypasses performed on patients with thromboangiitis obliterans, primary and secondary patency rates were 50 and 63 percent at 5 years, and 43 and 56 percent at 10 years, respectively [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/94\" class=\"abstract_t\">94</a>]. The 10-year patency rates of the postoperative non-smoking group were significantly higher than that of the smoking group (67 versus 35 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another study, revascularization was performed in 19 patients and the cumulative secondary patency rate was 58 percent at a mean of 5.4 years follow up [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/93\" class=\"abstract_t\">93</a>]. The limb salvage rate was 96 percent with seven major and 36 minor amputations performed. These authors noted that, although the long-term patency of the bypass grafts was low, short-term patency was sufficient to allow healing of ischemic lesion. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Similarly, in another study of 27 patients with thromboangiitis obliterans who underwent revascularization, patency rates at 12, 24, and 36 months were 59, 48, and 33 percent, respectively [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/7\" class=\"abstract_t\">7</a>]. The limb salvage rate, however, was 93 percent. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a consecutive series of 17 patients with thromboangiitis and critical limb ischemia in 20 limbs were revascularized using endovascular means. Technical success was achieved in 95 percent. During a mean follow-up of two years, amputation-free survival was 84.2 percent [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/98\" class=\"abstract_t\">98</a>]. </p><p/><p>Endovascular intervention including thrombolytic therapy or angioplasty has undergone limited investigation in patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/98,99\" class=\"abstract_t\">98,99</a>]. In one study of 11 patients with longstanding disease who had gangrene or pregangrenous lesions of the toes or feet, treatment with low-dose intraarterial streptokinase resulted in avoidance or alteration in the level of amputation in 58 percent of patients [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/99\" class=\"abstract_t\">99</a>]. However, further study is required before the precise role of thrombolytic therapy can be defined. In our experience, thrombolytic therapy is rarely used because of its limited benefit. </p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Sympathectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lumbar or thoracic sympathectomy improves pain control in other vascular occlusive diseases, but its role in the treatment of patients with thromboangiitis remains unclear. There have been several reports demonstrating that sympathectomy can be safely and effectively used in these patients [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/15,100\" class=\"abstract_t\">15,100</a>]. Laparoscopic sympathectomy in the lower [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/101,102\" class=\"abstract_t\">101,102</a>] and upper extremities [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/103\" class=\"abstract_t\">103</a>] has been performed. Although sympathectomy anecdotally benefits some individuals, there are no data to guide patient choice. (See <a href=\"topic.htm?path=medical-thoracoscopy-pleuroscopy-diagnostic-and-therapeutic-applications\" class=\"medical medical_review\">&quot;Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H87009583\"><span class=\"h2\">Other interventions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As with other forms of chronic critical limb ischemia, spinal cord stimulation has been used to manage pain in patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/104-107\" class=\"abstract_t\">104-107</a>]. (See <a href=\"topic.htm?path=treatment-of-chronic-limb-threatening-ischemia#H31\" class=\"medical medical_review\">&quot;Treatment of chronic limb-threatening ischemia&quot;, section on 'Spinal cord stimulation'</a>.)</p><p class=\"headingAnchor\" id=\"H87000741\"><span class=\"h1\">OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two studies have evaluated the long-term outcomes, including rates for major and minor amputations and survival in patients with thromboangiitis obliterans [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/13,66\" class=\"abstract_t\">13,66</a>]. </p><p>One study followed 110 patients with thromboangiitis obliterans for a mean of 10.6 years [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/66\" class=\"abstract_t\">66</a>]. The cumulative survival rate was 84 percent up to 25 years after the initial consultation. The rate for any kind of amputation (upper or lower limb) was 43 percent with 12 percent being major amputations. Forty-one patients who stopped smoking did not undergo major amputation and of 69 patients who continued smoking, 19 percent required major amputation. No ischemic ulcers occurred or recurred in patients older than 60 years. </p><p>Another study followed 111 patients with proven thromboangiitis obliterans for a mean of 15 years [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/13\" class=\"abstract_t\">13</a>]. The risk of major amputation was 11 percent at 5 years, 21 percent at 10 years and 23 percent at 20 years. As in virtually every other study published, tobacco abstinence was associated with a good prognosis. In this study: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of amputation in former smokers was eliminated by 8 years after smoking cessation </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of amputation continued in patients who continued to smoke</p><p/><p>This study, however, found reduced life-expectancy in patients with thromboangiitis obliterans compared with the remainder of the population in the United States. The average age of death was 52 years. Older age at time of diagnosis was associated with an increased risk of death. Patients with anticardiolipin antibodies have a younger age of onset and an increased rate of major amputations [<a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H234644142\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thromboangiitis obliterans is a vasculitis that affects medium and small arteries, veins and nerves in the extremities, with rare involvement of visceral and cerebral vessels. Patients are predominantly young smokers who present with distal extremity ischemia, ischemic digit ulcers, or digit gangrene. The disease is strongly associated with the use of tobacco products. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H5\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The disease is characterized by segmental inflammatory thrombotic vessel occlusions. It is distinguished pathologically from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus with relative sparing of the vessel wall and, more specifically, sparing of the internal elastic lamina. Although smoking is important to the pathogenesis, the specific etiologic mechanism remains unknown. Inflammatory, immunologic, and endothelial factors play a role. (See <a href=\"#H514794264\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The evaluation of thromboangiitis obliterans consists of history and physical examination, vascular evaluation, and laboratory examination to serologically rule out other etiologies that can cause small and medium vessel occlusive arterial disease. (See <a href=\"#H514794398\" class=\"local\">'Clinical and laboratory evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical diagnosis can be established with the following commonly used criteria:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Age less than 45 years</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Current or recent history of tobacco use</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Distal extremity ischemia (objectively noted on vascular testing) (See <a href=\"#H87000089\" class=\"local\">'Vascular evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Typical arteriographic findings of thromboangiitis obliterans (See <a href=\"#H9\" class=\"local\">'Imaging studies'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (<a href=\"image.htm?imageKey=SURG%2F68663\" class=\"graphic graphic_table graphicRef68663 \">table 1</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging studies are not necessary to establish a diagnosis but may be performed in patients whose clinical features are not definitive. When imaging is performed, features suggestive of thromboangiitis obliterans include lack of atherosclerosis, no proximal source for embolism, the involvement of small and medium-sized vessels, segmental vascular occlusion, and collateralization around areas of occlusion (ie, corkscrew collaterals). However, the finding of corkscrew collaterals is nonspecific. (See <a href=\"#H9\" class=\"local\">'Imaging studies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biopsy of a subcutaneous nodule or superficial thrombophlebitis showing typical acute phase changes provides a definitive diagnosis, but biopsy is not usually needed. (See <a href=\"#H461453879\" class=\"local\">'Biopsy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients diagnosed with thromboangiitis obliterans, we recommend smoking cessation (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). Smoking cessation reduces symptoms and decreases the risk for major amputation. Continued smoking is associated with an overall amputation rate of 40 to 50 percent. (See <a href=\"#H12\" class=\"local\">'Smoking cessation'</a> above and <a href=\"topic.htm?path=overview-of-smoking-cessation-management-in-adults\" class=\"medical medical_review\">&quot;Overview of smoking cessation management in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other treatments used to manage pain associated with critical ischemia include <a href=\"topic.htm?path=iloprost-drug-information\" class=\"drug drug_general\">iloprost</a> infusion, sympathectomy and spinal cord stimulation. Calcium channel blockers and intermittent pneumatic compression indirectly improve pain by increasing blood flow. (See <a href=\"#H11\" class=\"local\">'Medical management'</a> above and <a href=\"#H87009583\" class=\"local\">'Other interventions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical revascularization is usually not indicated due to the distal nature of occlusive disease and because most patients do well with smoking cessation. Bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Although the long&ndash;term patency rates are inferior to those seen with peripheral artery disease due to atherosclerosis, limb salvage rates are generally greater than 90 percent and may be more correlated to smoking cessation. (See <a href=\"#H17\" class=\"local\">'Revascularization'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H2863160265\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We are saddened by the death of Emile R Mohler, III, MD, who passed away in October 2017. UpToDate wishes to acknowledge Dr. Mohler's past work as an original contributor for this topic, as well as his work as our Section Editor for Vascular Medicine.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/1\" class=\"nounderline abstract_t\">Buerger L. Landmark publication from the American Journal of the Medical Sciences, 'Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene'. 1908. Am J Med Sci 2009; 337:274.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/2\" class=\"nounderline abstract_t\">Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010; 121:1858.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/3\" class=\"nounderline abstract_t\">Dargon PT, Landry GJ. Buerger's disease. Ann Vasc Surg 2012; 26:871.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/4\" class=\"nounderline abstract_t\">Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000; 343:864.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/5\" class=\"nounderline abstract_t\">Mills JL, Porter JM. Buerger's disease: a review and update. Semin Vasc Surg 1993; 6:14.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/6\" class=\"nounderline abstract_t\">Grove WJ, Stansby GP. Buerger's disease and cigarette smoking in Bangladesh. Ann R Coll Surg Engl 1992; 74:115.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/7\" class=\"nounderline abstract_t\">Dilege S, Aksoy M, Kayabali M, et al. Vascular reconstruction in Buerger's disease: is it feasible? Surg Today 2002; 32:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/8\" class=\"nounderline abstract_t\">Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta Pathol Jpn 1989; 39:153.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/9\" class=\"nounderline abstract_t\">Lie JT. Thromboangiitis obliterans (Buerger's disease) in women. Medicine (Baltimore) 1987; 66:65.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/10\" class=\"nounderline abstract_t\">Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006; 1:14.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/11\" class=\"nounderline abstract_t\">Mills JL, Taylor LM Jr, Porter JM. Buerger's disease in the modern era. Am J Surg 1987; 154:123.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/12\" class=\"nounderline abstract_t\">Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82:IV3.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/13\" class=\"nounderline abstract_t\">Cooper LT, Tse TS, Mikhail MA, et al. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol 2004; 44:2410.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/14\" class=\"nounderline abstract_t\">Ehrenfeld M, Adar R. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). J Rheumatol 2000; 27:1818.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/15\" class=\"nounderline abstract_t\">Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg 1997; 67:264.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/16\" class=\"nounderline abstract_t\">Shionoya S, Ban I, Nakata Y, et al. Involvement of the iliac artery in Buerger's disease (pathogenesis and arterial reconstruction). J Cardiovasc Surg (Torino) 1978; 19:69.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/17\" class=\"nounderline abstract_t\">Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol 2000; 75 Suppl 1:S175.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/18\" class=\"nounderline abstract_t\">Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg 1991; 5:570.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/19\" class=\"nounderline abstract_t\">Papa M, Bass A, Adar R, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 1992; 111:527.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/20\" class=\"nounderline abstract_t\">Tavakoli H, Rezaii J, Esfandiari K, et al. Buerger's disease: a 10-year experience in Tehran, Iran. Clin Rheumatol 2008; 27:369.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/21\" class=\"nounderline abstract_t\">Martin-Blondel G, Koskas F, Cacoub P, S&egrave;ne D. Is thromboangiitis obliterans presentation influenced by cannabis addiction? Ann Vasc Surg 2011; 25:469.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/22\" class=\"nounderline abstract_t\">Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 1988; 31:812.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/23\" class=\"nounderline abstract_t\">Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. Br J Dermatol 2005; 152:166.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/24\" class=\"nounderline abstract_t\">Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited--ten new case reports. Angiology 2001; 52:1.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/25\" class=\"nounderline abstract_t\">Cottencin O, Karila L, Lambert M, et al. Cannabis arteritis: review of the literature. J Addict Med 2010; 4:191.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/26\" class=\"nounderline abstract_t\">Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42:107.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/27\" class=\"nounderline abstract_t\">Chen YW, Nagasawa T, Wara-Aswapati N, et al. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J Clin Periodontol 2009; 36:830.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/28\" class=\"nounderline abstract_t\">Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am 1990; 16:269.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/29\" class=\"nounderline abstract_t\">Ma&#322;ecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis 2009; 206:328.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/30\" class=\"nounderline abstract_t\">Leu HJ. Early inflammatory changes in thromboangiitis obliterans. Pathol Microbiol (Basel) 1975; 43:151.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/31\" class=\"nounderline abstract_t\">Lie JT. Thromboangiitis obliterans (Buerger's disease) revisited. Pathol Annu 1988; 23 Pt 2:257.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/32\" class=\"nounderline abstract_t\">Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308:1113.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/33\" class=\"nounderline abstract_t\">Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 2003; 25:451.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/34\" class=\"nounderline abstract_t\">Kobayashi M, Ito M, Nakagawa A, et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 1999; 29:451.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/35\" class=\"nounderline abstract_t\">Guzel E, Topal E, Yildirim A, et al. Targeting novel antigens in the arterial wall in thromboangiitis obliterans. Folia Histochem Cytobiol 2010; 48:134.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/36\" class=\"nounderline abstract_t\">Edo N, Miyai K, Ogata S, et al. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes. Cardiovasc Pathol 2010; 19:59.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/37\" class=\"nounderline abstract_t\">Dellalibera-Joviliano R, Joviliano EE, Silva JS, Evora PR. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol 2012; 170:28.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/38\" class=\"nounderline abstract_t\">Tamai H, Kobayashi M, Takeshita K, et al. Possible involvement of Notch signaling in the pathogenesis of Buerger's disease. Surg Today 2014; 44:307.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/39\" class=\"nounderline abstract_t\">Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998; 315:17.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/40\" class=\"nounderline abstract_t\">Azizi M, Boutouyrie P, Bura-Rivi&egrave;re A, et al. Thromboangiitis obliterans and endothelial function. Eur J Clin Invest 2010; 40:518.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/41\" class=\"nounderline abstract_t\">Joras M, Poredos P, Fras Z. Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation. Eur J Clin Invest 2006; 36:376.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/42\" class=\"nounderline abstract_t\">Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996; 94:II211.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/43\" class=\"nounderline abstract_t\">Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002; 7:259.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/44\" class=\"nounderline abstract_t\">Hus I, Sokolowska B, Walter-Croneck A, et al. Assessment of plasma prothrombotic factors in patients with Buerger's disease. Blood Coagul Fibrinolysis 2013; 24:133.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/45\" class=\"nounderline abstract_t\">Pu&eacute;chal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007; 46:192.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/46\" class=\"nounderline abstract_t\">Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18:18.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/47\" class=\"nounderline abstract_t\">Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud syndrome with thromboangiitis obliterans--a meta-analysis. Angiology 2012; 63:315.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/48\" class=\"nounderline abstract_t\">Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. J Thorac Cardiovasc Surg 1997; 113:800.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/49\" class=\"nounderline abstract_t\">Lie JT. Visceral intestinal Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S249.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/50\" class=\"nounderline abstract_t\">Kurata A, Nonaka T, Arimura Y, et al. Multiple ulcers with perforation of the small intestine in buerger's disease: a case report. Gastroenterology 2003; 125:911.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/51\" class=\"nounderline abstract_t\">Cakmak A, Gyedu A, Akyol C, et al. Occlusion of the celiac trunk, the inferior mesenteric artery and stenosis of the superior mesenteric artery in peripheral thrombangiitis obliterans. Vasa 2009; 38:394.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/52\" class=\"nounderline abstract_t\">Michail PO, Filis KA, Delladetsima JK, et al. Thromboangiitis obliterans (Buerger's disease) in visceral vessels confirmed by angiographic and histological findings. Eur J Vasc Endovasc Surg 1998; 16:445.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/53\" class=\"nounderline abstract_t\">Fujii Y, Soga J, Hidaka T, et al. Color doppler flows of corkscrew collaterals in Thromboangiitis obliterans (Buerger's disease) using color duplex ultrasonography. J Am Coll Cardiol 2011; 57:2539.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/54\" class=\"nounderline abstract_t\">Pereira de Godoy JM, Braile DM. Buerger's disease and anticardiolipin antibodies. J Cardiovasc Med (Hagerstown) 2009; 10:792.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/55\" class=\"nounderline abstract_t\">Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S243.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/56\" class=\"nounderline abstract_t\">Shionoya S. What is Buerger's disease? World J Surg 1983; 7:544.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/57\" class=\"nounderline abstract_t\">Dimmick SJ, Goh AC, Cauzza E, et al. Imaging appearances of Buerger's disease complications in the upper and lower limbs. Clin Radiol 2012; 67:1207.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/58\" class=\"nounderline abstract_t\">Lambeth JT, Yong NK. Arteriographic findings in thromboangiitis obliterans with emphasis on femoropopliteal involvement. Am J Roentgenol Radium Ther Nucl Med 1970; 109:553.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/59\" class=\"nounderline abstract_t\">Yoshimuta T, Akutsu K, Okajima T, et al. Corkscrew collaterals in Buerger's disease. Can J Cardiol 2009; 25:365.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/60\" class=\"nounderline abstract_t\">Marder VJ, Mellinghoff IK. Cocaine and Buerger disease: is there a pathogenetic association? Arch Intern Med 2000; 160:2057.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/61\" class=\"nounderline abstract_t\">No&euml;l B. Cocaine and arsenic-induced Raynaud's phenomenon. Clin Rheumatol 2002; 21:343.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/62\" class=\"nounderline abstract_t\">Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996; 11:335.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/63\" class=\"nounderline abstract_t\">Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006; 5:89.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/64\" class=\"nounderline abstract_t\">Canter HI, Isci E, Erk Y. Vacuum-assisted wound closure for the management of a foot ulcer due to Buerger's disease. J Plast Reconstr Aesthet Surg 2009; 62:250.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/65\" class=\"nounderline abstract_t\">Hurt RD, Hays JT. Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans. Mayo Clin Proc 2008; 83:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/66\" class=\"nounderline abstract_t\">Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39:176.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/67\" class=\"nounderline abstract_t\">Hooten WM, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo Clin Proc 1998; 73:529.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/68\" class=\"nounderline abstract_t\">Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998; 15:300.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/69\" class=\"nounderline abstract_t\">Fiessinger JN, Sch&auml;fer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990; 335:555.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/70\" class=\"nounderline abstract_t\">Bozkurt AK, K&ouml;ksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006; 25:162.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/71\" class=\"nounderline abstract_t\">Bozkurt AK, Cengiz K, Arslan C, et al. A stable prostacyclin analogue (iloprost) in the treatment of Buerger's disease: a prospective analysis of 150 patients. Ann Thorac Cardiovasc Surg 2013; 19:120.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/72\" class=\"nounderline abstract_t\">Cacione DG, Macedo CR, Baptista-Silva JC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev 2016; 3:CD011033.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/73\" class=\"nounderline abstract_t\">Labropoulos N, Watson WC, Mansour MA, et al. Acute effects of intermittent pneumatic compression on popliteal artery blood flow. Arch Surg 1998; 133:1072.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/74\" class=\"nounderline abstract_t\">Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int Angiol 2002; 21:360.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/75\" class=\"nounderline abstract_t\">Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28:964.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/76\" class=\"nounderline abstract_t\">Kim HJ, Jang SY, Park JI, et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36:336.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/77\" class=\"nounderline abstract_t\">Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011; 4:15.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/78\" class=\"nounderline abstract_t\">Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209:10.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/79\" class=\"nounderline abstract_t\">Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/80\" class=\"nounderline abstract_t\">Motukuru V, Suresh KR, Vivekanand V, et al. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg 2008; 48:53S.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/81\" class=\"nounderline abstract_t\">Saito S, Nishikawa K, Obata H, Goto F. Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans. Angiology 2007; 58:429.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/82\" class=\"nounderline abstract_t\">Durdu S, Akar AR, Arat M, et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006; 44:732.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/83\" class=\"nounderline abstract_t\">Boda Z, Udvardy M, R&aacute;zs&oacute; K, et al. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger's disease. Clin Appl Thromb Hemost 2009; 15:552.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/84\" class=\"nounderline abstract_t\">Baumann G, Stangl V, Klein-Weigel P, et al. Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study. Clin Res Cardiol 2011; 100:683.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/85\" class=\"nounderline abstract_t\">Inan M, Alat I, Kutlu R, et al. Successful treatment of Buerger's Disease with intramedullary K-wire: the results of the first 11 extremities. Eur J Vasc Endovasc Surg 2005; 29:277.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/86\" class=\"nounderline abstract_t\">Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006; 114:2679.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/87\" class=\"nounderline abstract_t\">De Haro J, Acin F, Bleda S, et al. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan. BMC Cardiovasc Disord 2012; 12:5.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/88\" class=\"nounderline abstract_t\">Narv&aacute;ez J, Garc&iacute;a-G&oacute;mez C, &Aacute;lvarez L, et al. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore) 2016; 95:e5511.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/89\" class=\"nounderline abstract_t\">Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35:48.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/90\" class=\"nounderline abstract_t\">Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 1985; 35:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/91\" class=\"nounderline abstract_t\">Dean SM, Satiani B. Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 2001; 6:245.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/92\" class=\"nounderline abstract_t\">Lee T, Ra HD, Park YJ, et al. New routing alternative for proximal anterior tibial artery bypass in patients with Buerger disease. J Vasc Surg 2011; 54:1839.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/93\" class=\"nounderline abstract_t\">Sayin A, Bozkurt AK, T&uuml;z&uuml;n H, et al. Surgical treatment of Buerger's disease: experience with 216 patients. Cardiovasc Surg 1993; 1:377.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/94\" class=\"nounderline abstract_t\">Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13:186.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/95\" class=\"nounderline abstract_t\">Singh I, Ramteke VK. The role of omental transfer in Buerger's disease: New Delhi's experience. Aust N Z J Surg 1996; 66:372.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/96\" class=\"nounderline abstract_t\">Agarwal VK. Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger's disease) and retinal avascular diseases (retinitis pigmentosa). Int Surg 2007; 92:174.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/97\" class=\"nounderline abstract_t\">Nishikimi N. Fate of limbs with failed vascular reconstruction in Buerger's disease patients. Int J Cardiol 2000; 75 Suppl 1:S183.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/98\" class=\"nounderline abstract_t\">Graziani L, Morelli L, Parini F, et al. Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases. Ann Vasc Surg 2012; 26:387.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/99\" class=\"nounderline abstract_t\">Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 1993; 78:54.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/100\" class=\"nounderline abstract_t\">Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol 2006; 111:147.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/101\" class=\"nounderline abstract_t\">Chander J, Singh L, Lal P, et al. Retroperitoneoscopic lumbar sympathectomy for buerger's disease: a novel technique. JSLS 2004; 8:291.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/102\" class=\"nounderline abstract_t\">Watarida S, Shiraishi S, Fujimura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. Surg Endosc 2002; 16:500.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/103\" class=\"nounderline abstract_t\">De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. Ann Thorac Surg 2002; 74:885.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/104\" class=\"nounderline abstract_t\">Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). J Vasc Surg 1999; 29:928.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/105\" class=\"nounderline abstract_t\">Chierichetti F, Mambrini S, Bagliani A, Odero A. Treatment of Buerger's disease with electrical spinal cord stimulation--review of three cases. Angiology 2002; 53:341.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/106\" class=\"nounderline abstract_t\">Pace AV, Saratzis N, Karokis D, et al. Spinal cord stimulation in Buerger's disease. Ann Rheum Dis 2002; 61:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/thromboangiitis-obliterans-buergers-disease/abstract/107\" class=\"nounderline abstract_t\">Donas KP, Schulte S, Ktenidis K, Horsch S. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg 2005; 41:830.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8205 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H234644142\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">RISK FACTORS</a></li><li><a href=\"#H514794264\" id=\"outline-link-H514794264\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL PRESENTATION</a></li><li><a href=\"#H514794398\" id=\"outline-link-H514794398\">CLINICAL AND LABORATORY EVALUATION</a><ul><li><a href=\"#H87000089\" id=\"outline-link-H87000089\">Vascular evaluation</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Laboratory tests</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Imaging studies</a></li></ul></li><li><a href=\"#H86999828\" id=\"outline-link-H86999828\">DIAGNOSIS</a><ul><li><a href=\"#H86999781\" id=\"outline-link-H86999781\">Clinical criteria</a></li><li><a href=\"#H461453879\" id=\"outline-link-H461453879\">Biopsy</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">MEDICAL MANAGEMENT</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Smoking cessation</a></li><li><a href=\"#H268457206\" id=\"outline-link-H268457206\">Iloprost</a></li><li><a href=\"#H268457398\" id=\"outline-link-H268457398\">Calcium channel blockers</a></li><li><a href=\"#H268457455\" id=\"outline-link-H268457455\">Intermittent pneumatic compression</a></li><li><a href=\"#H268457277\" id=\"outline-link-H268457277\">Experimental therapies</a></li></ul></li><li><a href=\"#H234644233\" id=\"outline-link-H234644233\">INTERVENTION</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">Revascularization</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Sympathectomy</a></li><li><a href=\"#H87009583\" id=\"outline-link-H87009583\">Other interventions</a></li></ul></li><li><a href=\"#H87000741\" id=\"outline-link-H87000741\">OUTCOMES</a></li><li><a href=\"#H234644142\" id=\"outline-link-H234644142\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H2863160265\" id=\"outline-link-H2863160265\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"SURG/8205|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/64278\" class=\"graphic graphic_diagnosticimage\">- Hand arteriogram in thromboangiitis obliterans</a></li></ul></li><li><div id=\"SURG/8205|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=SURG/59478\" class=\"graphic graphic_picture\">- Histologic changes in thromboangiitis obliterans </a></li><li><a href=\"image.htm?imageKey=SURG/80866\" class=\"graphic graphic_picture\">- Ulcerations and gangrene in thromboangiitis obliterans</a></li><li><a href=\"image.htm?imageKey=CARD/79685\" class=\"graphic graphic_picture\">- The Allen test</a></li></ul></li><li><div id=\"SURG/8205|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=SURG/68663\" class=\"graphic graphic_table\">- Differential diagnosis of thromboangiitis obliterans</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=arterial-blood-gases\" class=\"medical medical_review\">Arterial blood gases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-assessment-of-wounds\" class=\"medical medical_review\">Clinical assessment of wounds</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-lower-extremity-peripheral-artery-disease\" class=\"medical medical_review\">Clinical features and diagnosis of lower extremity peripheral artery disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-raynaud-phenomenon\" class=\"medical medical_review\">Clinical manifestations and diagnosis of the Raynaud phenomenon</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-endothelial-dysfunction-clinical-aspects\" class=\"medical medical_review\">Coronary artery endothelial dysfunction: Clinical aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=echocardiography-in-detection-of-cardiac-and-aortic-sources-of-systemic-embolism\" class=\"medical medical_review\">Echocardiography in detection of cardiac and aortic sources of systemic embolism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors\" class=\"medical medical_review\">Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-the-raynaud-phenomenon\" class=\"medical medical_review\">Initial treatment of the Raynaud phenomenon</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-thoracoscopy-pleuroscopy-diagnostic-and-therapeutic-applications\" class=\"medical medical_review\">Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=negative-pressure-wound-therapy\" class=\"medical medical_review\">Negative pressure wound therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-diagnosis-of-arterial-disease\" class=\"medical medical_review\">Noninvasive diagnosis of arterial disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults\" class=\"medical medical_review\">Overview of and approach to the vasculitides in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-smoking-cessation-management-in-adults\" class=\"medical medical_review\">Overview of smoking cessation management in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-limb-threatening-ischemia\" class=\"medical medical_review\">Treatment of chronic limb-threatening ischemia</a></li></ul></div></div>","javascript":null}